

2020 ONCOLOGY ANNUAL REPORT



PARK NICOLLET FRAUENSHUH CANCER CENTER
REGIONS HOSPITAL CANCER CARE CENTER
PARK NICOLLET CLINIC & SPECIALTY CENTER - BURNSVILLE
PARK NICOLLET CLINIC & SPECIALTY CENTER - MAPLE GROVE
HUTCHINSON HEALTH CANCER CENTER
LAKEVIEW HOSPITAL CANCER CARE - STILLWATER



Providing
outstanding
oncology care
at 13 locations



Randy Hurley, MD
Medical Director, HealthPartners and
Regions Hospital Cancer Care Center
randy.w.hurley@healthpartners.com



Mark A. Wilkowske, MD
Medical Director, Park Nicollet
Frauenshuh Cancer Center
mark.wilkowske@parknicollet.com



Laura Holasek
Administrative System Director
Oncology Services
laura.holasek@parknicollet.com

Change and uncertainty brings innovation and opportunity

COVID-19 has brought unprecedented change in the care of people with cancer. Delaying diagnosis and treatment for someone with a potentially life-threatening condition wasn't an option. Knowing that our patients were counting on us, we took this time of change and uncertainty to find innovative ways to continue providing safe, high-quality care.

We rapidly reviewed every aspect of our care to ensure that our patients continued to receive essential, in-person services while minimizing exposure to the virus. Whenever possible, video visits allowed patients to talk with their doctor and receive personalized care from home. Support groups were moved online to maintain those important connections. New policies designed to monitor and track the virus were quickly adopted by staff. A new care protocol for patients experiencing respiratory symptoms meant that those patients continued to be treated while other patients stayed protected. The result was cancer care that felt safe and effective for patients and staff.

Timely, expert care has always been a priority for newly-diagnosed patients. With the pandemic, it's even more important for people to know that their care won't be postponed. That's why we haven't wavered from our commitment to see patients

within 48 hours of a diagnosis. That's followed up with a care plan that's personalized to each patient's needs and specific type of cancer. We're proud of our reputation as regionally renowned experts in treating many cancers, including:

- Brain cancer
- Breast cancer
- Gastrointestinal cancer
- Genitourinary cancer
- Gynecologic cancer
- Kidney cancer
- Leukemia and lymphoma
- Lung cancer
- Melanoma
- Pancreatic cancer

The important work at our Cancer Research Center hasn't stopped, either. Proven and newly emerging treatments can significantly impact a patient's treatment options. Our patients have access to a growing number of pre-clinical, phase 1, 2 and 3 clinical trials, as well as a number of research trials and quality improvement programs. Now more than ever, patients want access to the latest treatment options close to home, without the potential health risks associated with traveling to distant cities.

Our program has continued to grow, however our locations have shifted as care patterns have changed. Our HealthPartners Riverside Clinic recently closed, with those patients and clinicians moving to other sites. At the same time, we're expanding our services at Park Nicollet Clinic & Specialty Center – Burnsville and at Regions Hospital in 2021.

During this stressful time, we've found ways to provide effective, safe care to our patients. Our commitment to providing the best care possible is demonstrated through our certification by the American College of Surgeons' Commission on Cancer and participation in the American Society of Clinical Oncology's Quality Oncology Practice Initiative (QOPI).

This report highlights our ongoing work in the caring for patients diagnosed with cancer. Please contact us if you have questions about this report or the care we offer.



ASCO'S QOPI CERTIFICATION





Cancer care locations


Minnesota

1. Lakeview Hospital Cancer Care – Stillwater
2. Park Nicollet Clinic & Specialty Center – Burnsville (Infusion Center)
3. Park Nicollet Clinic & Specialty Center – Maple Grove (Infusion Center)
4. Park Nicollet Frauenshuh Cancer Center
5. Regions Hospital Cancer Care Center
6. St. Francis Cancer Center*
7. Hutchinson Health Cancer Center

Wisconsin

8. Amery Hospital and Clinic – Cancer Center of Western Wisconsin*
9. Hudson Hospital – Cancer Center of Western Wisconsin*
10. Osceola Medical Center – Cancer Center of Western Wisconsin*
11. St. Croix Regional Medical Center – Cancer Center of Western Wisconsin*
12. Western Wisconsin Health – Cancer Center of Western Wisconsin*
13. Westfields Hospital – Cancer Center of Western Wisconsin*

*HealthPartners provides physician services in partnership with these locations



Highlights of 2020

New Melanoma Clinic at Regions Hospital

This new clinic is a joint effort between HealthPartners Dermatology and HealthPartners Hematology/Oncology. While melanoma is highlighted in the clinic's name, treatment and care for all forms of skin cancers, as well as rashes related to chemotherapy treatment is provided.

The dermatology component is led by Warren Goodman, MD, a dermatologist with exceptional understanding and experience in the field. He is also the medical director of Dermatopathology at Regions Hospital. The oncology portion is led by Arek Dudek, MD, a renowned melanoma medical oncology expert providing patients with local and systemic immunotherapy, targeted therapy, and access to experimental therapeutics when needed. James Schlaefer, MD, an experienced and compassionate oncologic surgeon rounds out the group, providing all forms of excisions for skin cancers. He has notable expertise in performing sentinel lymph node biopsies.

This clinic is unique in offering dermatology, oncology and dermatopathology services in the same facility. It's located at Regions Hospital and services include:

- Full skin evaluations for patients who have been diagnosed with melanoma or skin cancer
- Caring discussions with patients regarding their condition, prognosis and ongoing monitoring
- Coordination of care for patients requiring skin cancer and melanoma excisions, as well as sentinel lymph node biopsies
- Coordination of care for patients requiring plastic surgery
- Cryotherapy
- Education and follow-up planning for those patients with a history of skin cancer or melanoma
- Evaluation and management of rashes and other skin conditions related and unrelated to systemic chemotherapy
- New lesion evaluation
- Skin biopsies of all types
- Surgical excisions and other surgical procedures for malignant skin lesions and problematic benign lesions
- Targeted therapy, immunotherapy and access to experimental trials of novel anticancer agents
- Topical chemotherapy

For more information or to make a referral, visit [regionshospital.com/cancer](https://www.regionshospital.com/cancer) or call **651-254-3572**.



Warren Goodman, MD



Arek Dudek, MD



James Schlaefer, MD



Highlights of 2020 continued

New CanCaRE Clinic to assist patients seeking medical cannabis

Up to 50% of patients being treated for cancer want more information on incorporating medical cannabis into their care. Research has shown that it may help reduce the severity of symptoms patients experience due to cancer such as pain, nausea and insomnia with few side effects. As an emerging field of care, many physicians lack the background to effectively guide their patients on issues such as eligibility, product availability and dosage recommendations.

HealthPartners and Park Nicollet recently launched a Cancer Research and Education (CanCaRE) Clinic to aid patients interested in learning more about adding medical cannabis to their treatment plan. A one-on-one, personalized education session over video can help answer questions about eligibility as well as the cost, safety and effectiveness of this type of care. The goal of the clinic is, “to make it easy for people to obtain reputable, fact-based information on medical cannabis,” according to Dylan Zylla, MD, MS, an oncologist and medical director of our CanCaRE Clinic and Cancer Research Center.

Clinic staff can also assist patients and their referring oncologists with the certification process through the Minnesota Department of Health.

Another facet of the clinic is access to leading-edge research trials. Our Cancer Research Center has been nationally recognized for its cannabis-related research and offers a variety of voluntary trials that are designed to better understand the role of cannabis in the treatment of people with cancer. According to Dr. Zylla, “As an evolving field of study, patient participation is key to better understanding the role of medical cannabis in alleviating suffering and maximizing the quality of life.”

For more information, email cancercannabis@healthpartners.com.

To make an appointment or a referral, call **952-993-2091**.



Dylan Zylla, MD, MS



Oncology and COVID-19

The COVID-19 pandemic disrupted all levels of health care, including oncology care. Knowing that patients would be understandably anxious if there were delays in their diagnosis or treatment of cancer, we quickly but thoughtfully reimagined our services. Our goal was to continue to provide high quality, personal care to our patients while minimizing exposure to the virus.

Video visits added to care options

Whenever possible, video visits are offered to patients. These visits provide the same personalized care and expert answers, but from the safety of home. For those times when in-person care is needed, steps are taken to ensure minimal risk of transmission of the virus. New distancing and mask protocols have been put in place for patients. Staff are administered personal protective equipment to wear and

trained in additional safety protocols designed to maintain a safe environment. Patients have expressed their appreciation for the continuity of their care despite the pandemic.

Classes moved online

Select patient education classes such as “Newly Diagnosed and After Treatment: Is What I’m Feeling Normal?” are now available as online videos. Easily accessible from home, these classes that traditionally took place in person, covered the common responses to a new cancer diagnosis, ideas for coping with the side effects of treatment, and the support services available to patients, families and caregivers.

Community education classes, including “Lung Cancer and Radon in our Homes,” were also moved online. Classes are taught by the same expert staff and include tangible next steps to screen or prevent cancer. Initial results from a

follow-up survey indicate that the participants found the online class helpful and engaging, while also saving on time. Further study will help determine if community classes should continue with an online option, even after the pandemic.

Support group sessions transitioned to video

Support groups for specific types of cancer moved to video group sessions. The opportunity for patients to connect with others with a similar diagnosis for support and encouragement continues to be highly rated by the participants and their family members.

Improved communication through MyChart

The use of MyChart was expanded to share educational materials and to communicate messages between visits. Many patients have preferred this change, reporting that this new system improved overall communications.



Highlights of 2020 continued



10th anniversary of palliative care and oncology

This year marks the 10th anniversary of palliative care's integration into HealthPartners and Park Nicollet Frauenshuh Cancer Center. Palliative care is specialized medical care that supports patients during a serious illness. Unlike hospice or end-of-life care, palliative care can be provided to anyone at any age or stage of their illness. A person can receive this type of care at the same time as medical treatment that cures an illness or prolongs life, such as chemotherapy, radiation, immune therapy or surgery. Recently, services expanded to include in-person, video and phone visits.

The goal of palliative care is to relieve pain, manage other symptoms, improve quality of life and reduce stress for patients and caregivers.

That includes providing extra support to patients as they face decisions about treatment options. In addition, when our patients are admitted to the hospital, palliative care services continue uninterrupted. The staff describes it as "caring for the whole patient, including the mind, body and soul."

In a recent review of our oncology program by American College of Surgeons' Commission on Cancer, embedding palliative care into our cancer care was listed as a top strength of our oncology program. We proudly mark this 10th anniversary and look forward to continuing to provide expert symptom management and compassionate care to all of our patients with cancer.

For more information, visit healthpartners.com/palliative.



Cancer center recertified

Park Nicollet Frauenshuh Cancer Center was recently recertified by the American College of Surgeons' Commission on Cancer. This organization recognizes programs that deliver comprehensive, high-quality, multidisciplinary, evidence-based and patient-centered care to their patients. It's a three-year certification that demonstrates our commitment to providing the best possible care to our patients.

New clinicians

- Turang Behbahani, MD
- Christine Ding, MD
- Levi Downs, MD
- Kristen Engstrom, NP-AGPC
- Kelsa Evans, PA-C
- Adrienne Mallen, MD
- Jayanthi Vijayakumar, MD

Expanding our services

Regions Hospital Cancer Care Center has received approval to expand infusion services on the hospital campus. This new space will focus on an improved patient experience, including spacious, private infusion rooms with the majority of them offering large windows. This thoughtful design will enhance patients' access to sunlight and nature, elements that are soothing during long chemotherapy treatments. More services will also be brought to patients as part of our non-moving patient care model. This type of care will allow our patients to conserve energy for the things they love to do. Construction on the new space is expected to begin in 2021.

Park Nicollet Clinic & Specialty Center – Burnsville recently added an 83,000 square-foot expansion, nearly doubling the size of its current space. The new facility, adjacent to the existing clinic, will offer a wide variety of services, including increased oncology services. The infusion center will provide expanded exam and infusion space to meet the growing needs of those needing cancer care and rheumatology services in the surrounding communities. The combination of renovated and new space will be available to serve patients in the spring of 2021.



Photo courtesy of Knutson Construction



Awards and achievements

Highly valued clinical mentor

Bal Jahagirdar, MD, received his fourth clinical mentor award from the University of Minnesota Hematology Oncology fellowship program. He was once again selected by hematology/oncology fellows as the most dedicated to their education out of all of the faculty at the University of Minnesota, Hennepin County Medical Center, Veteran's Administration Hospital and Regions Hospital. Faculty are only eligible every three years for this award. Dr. Jahagirdar has received this award every year he has been eligible.

Most Valuable Partner for the Month award

Cassy Lenz, RN, MSN, supervisor at Regions Hospital's infusion care center, was recognized with the hospital's Most Valuable Partner award in November. This award is given to staff who demonstrate values of compassion, excellence, integrity and partnership in their job. Cassy was nominated by her colleagues for providing the best care and experience to patients, families and team members.

Educational scholarship recipient

Annie Barlow, MPAS, PA-C, was the recipient of a Minnesota Society of Clinical Oncology's (MSCO) 2020 Educational Award for allied Health professionals. She will receive \$2,000 to attend an educational conference of her choice.

Finalist for Minnesota Nurse of the Year award

Cindy Olive, RN, OCN, was a finalist for the March of Dimes Minnesota Nurse of the Year award. This prestigious award recognizes local nurses for their outstanding work and compassionate care. Each year, nurses are nominated by peers, family or friends. Finalists are then selected by a team of qualified nurses. With the COVID-19 pandemic, this award put a spotlight on the extraordinary contributions of nurses. Awards were presented during a special virtual ceremony on October 23.

Dedicated to providing excellent care

Our patients would strongly recommend our clinicians at HealthPartners and Park Nicollet, according to the National Research Corporation.

96.5%

Would recommend

96.6%

Spent enough time with patient

97.5%

Provider listened

95.7%

Provider showed respect for what the patient said

Community awareness and support



HealthPartners and Park Nicollet oncology programs are actively involved in programs to increase cancer screenings, community awareness and support for patients with cancer.

Brain Cancer Support Group

At our brain tumor support group, patients and families virtually meet to share their feelings and concerns. The group strives to provide a sense of belonging, safety and courage to those affected by a brain tumor.

Lung Cancer Support Group

This monthly group at Regions Hospital provides an opportunity for patients with lung cancer to connect. The COVID-19 pandemic brought fear and uncertainty to many patients. In May, the group transitioned to virtual meetings and continued to be a highlight for many participants. There's a sense of empowerment and belonging when meeting others with a similar cancer diagnosis. As a patient shared, "It's just so different to be with people who are really walking in the same shoes."

A Breath of Hope Lung Foundation

This organization fights lung cancer by funding innovative research, raising awareness and supporting patients and families. We are fortunate to have Breath of Hope support our virtual lung cancer support group as well as other educational opportunities for our patients, including:

- **Holiday Healing with Kelly Groslags** – Stories that guide listeners through personal discoveries to help make positive changes in their lives
- **Patient Education Stories: Appointments, test results and managing anxiety with Terry Kast** – Providing insights and support to listeners
- **Virtual Lung Cancer Summit** – A patient education day held in November 2020 with variable topics including yoga, legal concerns, sexual dysfunction, clinical trials, parenting through cancer, and mutations and biomarkers



Education and research

Critical to our mission of helping patients with cancer is our engagement in education and research. Teaching and education ensure our clinicians and staff keep pace with new discoveries in the diagnosis and treatment of cancer. Research, through participation in clinical trials, gives our patients access to new therapies.

We're also taking a leading role in local research by developing an Early Phase Therapeutics Program (EPTP) at Regions Hospital. We offer a variety of clinical trials at all of our facilities that not only prevent and treat cancer, but also treat symptoms and side effects of cancer therapies. The Metro-Minnesota Community Oncology Research Consortium (**mmcorc.org**) is a nonprofit research consortium of 25 local hospitals and clinics, which provides people in our community access to the newest therapies available for cancer treatment and prevention through national cancer clinical trials. HealthPartners and Park Nicollet are active partners within the research consortium, which is administered by HealthPartners Institute. Physicians Dan Anderson, MD, MPH, and Richard Peterson, MD, provide consortium leadership as the principal investigator and assistant principal investigator.

For more information on our Cancer Research Center, visit healthpartners.com/institute.

Select trials

AB928CSP002: A Phase I/Ib Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Breast and Gynecologic Malignancies

ACT FAST 2018-07: Blood and Stool Sample Collection in Subjects with a Diagnosis of Colorectal Cancer or Colorectal Lesion

ALK4230-001: A Phase 1/2 Study of ALKS 4230 Administered SC as Monotherapy in Combo with Pembrolizumab in Subjects with Advanced Solid Tumors (ARTISTRY-2)

ARRAY 818-103: A Sequential 2-arm, Open-label Phase 1 Study to Evaluate Effects of Encorafenib in Combination with Binimetinib on the Pharmacokinetics of Losartan, Midazolam, Caffeine, Omeprazole, and Dextromethorphan Administered in a Cocktail Approach and on the Pharmacokinetics of Rosuvastatin in Patients with BRAF V600-mutant Unresectable or Metastatic Advanced Solid Tumors

CLEE011012301C: A Phase 3, Multicenter, Randomized, Open-label Trial to Evaluate Efficacy and Safety of Ribociclib with Endocrine Therapy as Adjuvant Treatment in Patients with HR+, HER2-negative, Early Breast Cancer

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

CX-839-012: A Phase 1b/2, Open label, Dose Escalation and Expansion Study of Glutaminase Inhibitor Telaglenastat (CB-839) in Combo with CDK4/6 Inhibitor Palbociclib in Patients with Advanced or Metastatic Solid Tumors

DF6002-001: A Phase 1/2, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF6002 as a Monotherapy and in Combination with Pembrolizumab in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications

Exact Sciences 2018-01 and 2018-01B: Blood and Stool Sample Collection to Evaluate Biomarkers in Subjects with Untreated Solid Tumors (breast, lung, prostate, bladder, uterine, kidney/renal pelvis, pancreatic, liver, stomach, ovarian, esophageal)

GNX-001: A Phase I Study of GNX102 in patients with Advanced Solid Tumors

HCRN GU15-215: A Phase 2 Trial of Atezolizumab and Bevacizumab in Cisplatin-ineligible Subjects with Advanced/Unresectable Urothelial Cancer

LUN 15-299: Phase II Study of Nivolumab + Ramucirumab for Patients with Previously-Treated Mesothelioma

MC17C1: Double-Blinded, Placebo-Controlled Trial to Explore the Anti-Androgen, Ketoconazole, for Treating Patients with an Ongoing EGFR Inhibitor Induced Rash

MK-7902-001 LEAP: A Phase 3 Randomized, Double-blind Trial of Pembrolizumab ± Lenvatinib in Participants with Treatment-naive, Metastatic NSCLC Whose Tumors have a TPS $\geq 1\%$

MRT516-005: A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab vs. Docetaxel in Patients with Advanced NSCLC with Disease Progression on or after Platinum-Based Chemotherapy in Combination with Checkpoint Inhibitor Therapy

NEKTAR PROPEL 16-214-05: A Phase 1b Open-Label, Multicenter Study to Investigate the Safety and Preliminary Efficacy of NKTR-214 in Combo with Anti-PD1 (Pembrolizumab) or Anti-PDL1 (Atezolizumab) in Patients with Locally Advanced or Metastatic Solid Tumors

PSB205-001: A Phase 1, Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of PSB205 in Patients with Relapsed/Refractory Solid Tumors

RGX110-001: A Phase 1 Study of RGX-104, a Small Molecule LXR Agonist, as a Single Agent and as Combination Therapy in Patients with Advanced Solid Malignancies and Lymphoma with an Expansion in Select Malignancies (NSCLC & SCLC)

SGNTV-001: Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors

SPOTLIGHT 8951-CL-0301: A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) + mFOLFOX6 vs. Placebo + mFOLFOX6 as First-line Treatment of Subjects with CLDN 18.2+, HER2-, Locally Advanced Unresectable or Metastatic Gastric or GEJ Adenocarcinoma

STELLAR-001: A Phase 2 Study of the anti-C5aR, IPH5401, in Combo with the Anti-PD-L1, Durvalumab, in Patients with Selected Advanced Solid Tumors

TAK981-1002: An Open Label, Dose-Escalation, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics, of TAK-981 in Adult Patients with Metastatic Solid Tumors or Lymphomas

TPX-0005-01: A Phase 1/2 Open Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

18-BI-1206-03: Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcγRIIB), in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors Previously Treated with Anti-PD1 or Anti-PDL1 Antibodies

Select publications

- Alkhateeb HB, Patnaik MM, Al-Kali A, Zblewski DL, Wallerich S, McTavish H, **Dudek AZ**. Phase 1b study of IGF-methotrexate conjugate in the treatment of high-grade myelodysplastic syndromes. *Anticancer Res*. 2020 Jul;40(7):3883-8.
- Calcaterra SL, Burnett-Hartman AN, Powers JD, Corley DA, McMullen CM, **Pawloski PA**, Feigelson HS. A population-based survey to assess the association between cannabis and quality of life among colorectal cancer survivors. *BMC Cancer*. 2020 May 3;20(1):373. PMC7197173.
- Demb J, Abraham L, Miglioretti DL, Sprague BL, O'Meara ES, Advani S, Henderson LM, Onega T, Buist DSM, **Schousboe JT**, Walter LC, Kerlikowske K, Braithwaite D, Breast Cancer Surveillance Consortium. Screening mammography outcomes: risk of breast cancer and mortality by comorbidity score and age. *J Natl Cancer Inst*. 2020 Jun 1;112(6):599-606. PMC7301094.
- Dudek AZ**, Liu LC, Fischer JH, Wiley EL, Sachdev JC, Bleeker J, **Hurley RW**, Tonetti DA, Thatcher GRJ, Venuti RP, O'Regan RM. Phase 1 study of TTC-352 in patients with metastatic breast cancer progressing on endocrine and CDK4/6 inhibitor therapy. *Breast Cancer Res Treat*. 2020 Oct;183(3):617-27.
- Dudek AZ**, Liu LC, Gupta S, Logan TF, Singer EA, Joshi M, Zakharia YN, Lang JM, Schwarz JK, Al-Janadi A, Alva AS. Phase Ib/II clinical trial of pembrolizumab with bevacizumab for metastatic renal cell carcinoma: BTCRC-GU14-003. *J Clin Oncol*. 2020 Apr 10;38(11):1138-45. PMC7145584.
- Dudek AZ**, Wang X, Gu L, Duong S, Stinchcombe TE, Kratzke R, Borghaei H, Vokes EE, Kindler HL. Randomized study of maintenance pemetrexed versus observation for treatment of malignant pleural mesothelioma: CALGB 30901. *Clin Lung Cancer*. 2020 Nov;21(6):553-61. PMC7606734.
- Han SY, **Jahagirdar BN**, **Dudek AZ**. Two malignancies with differential responses to immune checkpoint inhibitors: a case report. *Anticancer Res*. 2020 May;40(5):2821-6.
- Hurley PJ**, Bose N, Jha G, Gargano M, Ottoson N, Gorden K, Rathmann B, Harrison B, Qiu X, **Dudek AZ**. Immunoglobulin restores immune responses to BTH1677 in patients with low levels of antibodies to beta-glucan. *Anticancer Res*. 2020 Mar;40(3):1467-73.
- Lee C, Check DK, Manace Brenman L, Kushi LH, Epstein MM, Neslund-Dudas C, **Pawloski PA**, Achacoso N, Laurent C, Fehrenbacher L, Habel LA. Adjuvant endocrine therapy for breast cancer patients: impact of a health system outreach program to improve adherence. *Breast Cancer Res Treat*. 2020 Feb;180(1):219-26. PMC7035197.
- Lonial S, Jacobus S, Fonseca R, Weiss M, Kumar S, Orlowski RZ, Kaufman JL, Yacoub AM, Buadi FK, O'Brien T, Matous JV, **Anderson DM**, Emmons RV, Mahindra A, Wagner LI, Dhodapkar MV, Rajkumar SV. Randomized trial of lenalidomide versus observation in smoldering multiple myeloma. *J Clin Oncol*. 2020 Apr 10;38(11):1126-37. PMC7145586.
- McBane RDn, Wysokinski WE, Le-Rademacher JG, Zemla T, Ashrani A, Tafur A, Perepu U, **Anderson DM**, Gundabolu K, Kuzma C, Perez Botero J, Leon Ferre RA, Henkin S, Lenz CJ, Houghton DE, Vishnu P, Loprinzi CL. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial. *J Thromb Haemost*. 2020 Feb;18(2):411-21.
- Parker WB, Allan PW, Waud WR, Hong J, Gilbert-Ross M, Achyut BR, Joshi D, **Behbahani TE**, Rab R, Ealick SE, Sorscher EJ. The use of *Trichomonas vaginalis* purine nucleoside phosphorylase to activate fludarabine in the treatment of solid tumors. *Cancer Chemother Pharmacol*. 2020 Mar;85(3):573-83. PMC7039746.
- Patel MR, Jacobson BA, **Ji Y**, Hebbel RP, Kratzke RA. Blood outgrowth endothelial cells as a cellular carrier for oncolytic vesicular stomatitis virus expressing Interferon- β in preclinical models of non-small cell lung cancer. *Transl Oncol*. 2020 Jul;13(7):100782. PMC7231872.
- Seiwert TY, Kochanny S, Wood K, Worden FP, Adkins D, Wade JL, Sleckman BG, **Anderson DM**, Brisson RJ, Karrison T, Stadler WM, Vokes EE. A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab-resistant head and neck cancer: the MAESTRO study. *Cancer*. 2020 Jul 15;126(14):3237-43.
- Steele GL**, **Dudek AZ**, **Gilmore GE**, **Richter SA**, **Olson DA**, **Eklund JP**, **Zylla DM**. Impact of pain, opioids, and the mu-opioid receptor on progression and survival in patients with newly diagnosed stage IV pancreatic cancer. *Am J Clin Oncol*. 2020 Aug;43(8):591-7.
- Stover AM, Urick BY, Deal AM, Teal R, Vu MB, Carda-Auten J, Jansen J, Chung AE, Bennett AV, Chiang A, Cleeland C, Deutsch Y, Tai E, **Zylla DM**, Williams LA, Pitzen C, Snyder C, Reeve B, Smith T, McNiff K, Cella D, Neuss MN, Miller R, Atkinson TM, Spears PA, Smith ML, Geoghegan C, Basch EM. Performance measures based on how adults with cancer feel and function: stakeholder recommendations and feasibility testing in six cancer centers. *JCO Oncol Pract*. 2020 Mar;16(3):e234-e50. PMC7069703.
- Sun MM, Seleme N, Chen JJ, Zekeridou A, Sechi E, Walsh RD, **Beebe JD**, Sabbagh O, Mejico LJ, Gratton S, Skidd PM, Bellows DA, Falardeau J, Fraser CL, Cappelen-Smith C, Haines SR, Hassanzadeh B, Seay MD, Subramanian PS, Williams Z, Gordon LK. Neuro-ophthalmic complications in patients treated with CTLA-4 and PD-1/PD-L1 checkpoint blockade. *J Neuroophthalmol*. 2020 Oct 28 [epub ahead of print].
- Temel JS, Sloan J, Zemla T, Greer JA, Jackson VA, El-Jawahri A, Kamdar M, Kamal A, Blinderman CD, Strand J, **Zylla DM**, Daugherty C, Furqan M, Obel J, Razaq M, Roeland EJ, Loprinzi C. Multisite, randomized trial of early integrated palliative and oncology care in patients with advanced lung and gastrointestinal cancer: Alliance A221303. *J Palliat Med*. 2020 Jul;23(7):922-9. PMC7307668.
- Trujillo EB, Shapiro AC, Stephens N, Johnson SJ, Mills JB, **Zimmerman AR**, Spees CK. Monitoring rates of malnutrition risk in outpatient cancer centers utilizing the malnutrition screening tool embedded into the electronic health record. *Journal of the Academy of Nutrition and Dietetics*. 2020 Dec 11.
- Zylla DM**, **Gilmore GE**, **Steele GL**, **Eklund JP**, **Wood CM**, **Stover AM**, **Shapiro AC**. Collection of electronic patient-reported symptoms in patients with advanced cancer using Epic MyChart surveys. *Support Care Cancer*. 2020 Jul;28(7):3153-63.

Training the next generation of oncologists

One of the core missions of our organization is to train the next generation of physicians and scientists to be leaders in the field of oncology. Regions Hospital is proud to host a clinical training site for the University of Minnesota Hematology and Oncology Fellowship Program. For more than 25 years, this training has included direct supervision of patient care, didactic lectures and informational teaching sessions. Each year, more than 50 hours of didactic lectures are provided to University of Minnesota medical students, internal medicine residents, hematology-oncology fellows, primary care and emergency room physicians, oncology nurses and pharmacists.



Screening and prevention

Lung cancer and radon in our homes

Radon is a colorless odorless gas found in our soil that can enter the home through a variety of ways and increase your risk for lung cancer. The average radon level in Minnesota is more than three times higher than the national average, putting our communities at higher risk for developing lung cancer.

In October, Arek Dudek, MD, and Kevin Collis, RN navigator, hosted a virtual presentation to patients and members of our community on why we should be concerned with radon levels. Participants were offered a free radon test kit provided by the Minnesota Department of Health and instructions on how to use it. Results were emailed directly to the participants along with recommendations on steps to take if radon levels are 4 pCi/L or greater.

A follow-up survey was emailed to participants to verify if their homes were tested and if any mitigation steps were recommended or completed. The results of the survey will be used to understand the impact of this presentation on our community.

Colorectal cancer screening

Symptoms of colorectal cancer often don't appear until the cancer is advanced, so regular screenings help find it early, when treatment is most successful. This year was particularly challenging with COVID-19, however our clinics continued to remind people to schedule their colorectal screening. Options include a colonoscopy or fecal immunochemical tests (FITs), an in-home stool sample kit for those who meet certain qualifications.



Be Pink and breast cancer awareness

Mammo a-go-go is a mobile mammography unit that visits local communities and events to make getting a mammogram easy. We have two in our fleet and we've found that people feel safe going into the truck for a screening during the pandemic. The units are part of our Be Pink campaign to encourage women in the Twin Cities to be aware, proactive and empowered with their breast health, including screenings and early breast cancer detection.

While this year has been very different, Be Pink continues as a beacon of hope for many. Park Nicollet Foundation's annual Be Pink event raised money for Park Nicollet Jane Brattain Breast Center's Mammo a-go-go Community Outreach Program. This program helps thousands of local women in need receive mammogram screenings, diagnostic services and breast health education. The event was held on Oct. 29, with over 250 people participating and raising close to \$125,000 with the help of generous matching donors.

Another Be Pink fundraising event is through our partnership with Country4 a Cause. This year, it was a virtual concert where attendees listened to Lee Brice sing many of his most popular songs. The support provided by generous donors will allow the Mammo a-go-go to travel approximately 31,000 miles throughout Minnesota offering mammograms to women in need.

Community well-being initiatives

According to the American Cancer Society, certain cancer deaths can be prevented by living healthier lifestyles and "making healthy choices like not smoking, staying at a healthy weight, eating right, keeping active and getting recommended screening tests." HealthPartners promotes health and well-being in our communities through a variety of projects and initiatives designed to increase activity, encourage better food and beverage choices and reduce the number of people who use tobacco or vape.

Quality measures

These quality measures indicate the portion of breast, colon, rectum and lung cancer patients treated according to recognized standards of care by diagnosis year. The results are reported to the Rapid Cancer Reporting System (RCRS) of the National Cancer Data Base (NCDB), a joint program of American College of Surgeons (ACoS) and American Cancer Society. NCDB is a nationwide oncology outcomes database for more than 1,500 commission-accredited cancer programs.

NCDB Select Breast Measures

		ESTIMATED PERFORMANCE RATES					
		HEALTHPARTNERS			PARK NICOLLET		
Breast Cancer		2017	2018	2019	2017	2018	2019
Radiation therapy is administered within 1 year (365 days) of diagnosis for women under age 70 receiving breast-conserving surgery for breast cancer.	PR/EPR	89.90%	90.32%	93.58%	94.35%	95.36%	94.23%
	95% CI	[83.96 – 95.84%]	[85.12 – 95.53%]	[88.98 – 98.18%]	[90.95 – 97.75%]	[92.01 – 98.72%]	[90.57 – 97.89%]
	BENCHMARK	90%	90%	90%	90%	90%	90%
Tamoxifen or third generation aromatase inhibitor is recommended or administered within 1 year (365 days) of diagnosis for women with AJCC T1cN0M0, or Stage IB – III hormone receptor-positive breast cancer.	PR/EPR	95.61%	92.68%	98.28%	98.10%	95.77%	96.36%
	95% CI	[91.85 – 99.37%]	[88.08 – 97.29%]	[95.91 – 100%]	[96.26 – 99.94%]	[92.47 – 99.08%]	[93.51 – 99.22%]
	BENCHMARK	90%	90%	90%	90%	90%	90%
Combination chemotherapy or chemo-immunotherapy (if HER2 positive) is recommended or administered within 4 months (120 days) of diagnosis for women under 70 with AJCC T1cN0M0, or Stage IB – III hormone receptor-negative breast cancer.	PR/EPR	90.91%	100%	100%	100%	100%	100%
	95% CI	[73.92% – 100%]	[100 – 100%]	[100 – 100%]	[100 – 100%]	[100 – 100%]	[100 – 100%]
	BENCHMARK	*	*	*	*	*	*
Radiation therapy is recommended or administered following any mastectomy within 1 year (365 days) of diagnosis of breast cancer for women with ≥ 4 positive regional lymph nodes.	PR/EPR	66.67%	86.67%	75.00%	91.67%	100%	87.50%
	95% CI	[28.95 – 100%]	[69.46 – 100%]	[44.99 – 100%]	[76.03 – 100%]	[100 – 100%]	[64.58 – 100%]
	BENCHMARK	90%	90%	90%	90%	90%	90%
Image or palpation-guided needle biopsy to the primary site is performed to establish diagnosis of breast cancer.	PR/EPR	95.02%	94.67%	94.95%	95.40%	97.37%	97.71%
	95% CI	[92.27 – 97.77%]	[92.12 – 97.21%]	[92.37 – 97.53%]	[93.63 – 97.16%]	[95.96 – 98.78%]	[96.42 – 98.99%]
	BENCHMARK	80%	80%	80%	80%	80%	80%

*No benchmark

NCDB Select Colon, Rectum and Lung Measures

Colon Cancer

		ESTIMATED PERFORMANCE RATES					
		HEALTHPARTNERS			PARK NICOLLET		
		2017	2018	2019	2017	2018	2019
At least 12 regional lymph nodes are removed and pathologically examined for resected colon cancer.	PR/EPR	94.44%	98.31%	100%	93.85%	91.30%	92.11%
	95% CI	[86.96 – 100%]	[95.01 – 100%]	[100 – 100%]	[88.00 – 99.69%]	[84.66 – 97.95%]	[86.04 – 98.17%]
	BENCHMARK	85%	85%	85%	85%	85%	85%
Adjuvant chemotherapy is recommended or administered within 4 months (120 days) of diagnosis for patients under the age of 80 with AJCC Stage III (lymph node positive) colon cancer.	PR/EPR	100%	83.33%	100%	100%	100%	85.71%
	95% CI	[100 – 100%]	[66.12 – 100%]	[100 – 100%]	[100 – 100%]	[100 – 100%]	[70.75 – 100%]
	BENCHMARK	*	*	*	*	*	*

Rectum Cancer

		HEALTHPARTNERS			PARK NICOLLET		
		2017	2018	2019	2017	2018	2019
Preoperative chemo and radiation are administered for clinical AJCC T3N0, T4N0, or Stage III; or Postoperative chemo and radiation are administered within 180 days of diagnosis for clinical AJCC T1-2N0 with pathologic AJCC T3N0, T4N0, or Stage III; or treatment is recommended; for patients under the age of 80 receiving resection for rectal cancer.	PR/EPR	60%	78.57%	84.62%	87.50%	66.67%	72.73%
	95% CI	[35.21 – 84.79%]	[57.08 – 100%]	[65 – 100%]	[71.29 – 100%]	[35.87 – 97.47%]	[46.41 – 99.05%]
	BENCHMARK	85%	85%	85%	85%	85%	85%

Lung Cancer

		HEALTHPARTNERS			PARK NICOLLET		
		2017	2018	2019	2017	2018	2019
Systemic chemotherapy is administered within 4 months to day preoperatively or day of surgery to 6 months postoperatively, or it is recommended for surgically resected cases with pathologic, lymph node-positive (pN1) and (pN2) NSCLC.	PR/EPR	100%	83.33%	100%	100%	83.33%	87.50%
	95% CI	[100 – 100%]	[53.51 – 100%]	[100 – 100%]	[100 – 100%]	[53.51 – 100%]	[64.58 – 100%]
	BENCHMARK	85%	85%	85%	85%	85%	85%
Surgery is not the first course of treatment for cN2, M0 lung cases.	PR/EPR	88.89%	93.75%	62.50%	100%	100%	100%
	95% CI	[68.36 – 100%]	[81.89 – 100%]	[28.95 – 96.05%]	[100 – 100%]	[100 – 100%]	[100 – 100%]
	BENCHMARK	85%	85%	85%	85%	85%	85%

*No benchmark







Oncology registry

Most common cancer sites

The four most common cancers for HealthPartners and Park Nicollet patients in 2019 (excluding skin cancers) were breast, prostate, lung and colorectal. These four sites account for 50 percent of all cases.

**TABLE 1:
2019 Four Most Common Cancer Sites**

Table 1 compares, by site and percentage, HealthPartners and Park Nicollet case totals with estimated number of cancer cases in Minnesota and the U.S.



**TABLE 2:
2019 Tumor Registry**

HealthPartners and Park Nicollet tumor registries contain a comprehensive profile of all newly diagnosed cancer using standards set by the American College of Surgeons.

	HEALTH PARTNERS		PARK NICOLLET	
	2018	2019	2018	2019
ANALYTIC CASES (includes physician office cases)*	2,664	2,561	2,825	2,783
NON-ANALYTIC CASES**	47	109	0	0
PERCENTAGE OF CASES PRESENTED AT TUMOR CONFERENCES (GENERAL, GYN, BREAST, LUNG)	24% (642)	25% (636)	22.1% (625)	22.7% (634)

*Analytic: cases diagnosed and/or having initial therapy at HealthPartners or Park Nicollet

**Non-analytic: cases having all initial therapy elsewhere, seen at HealthPartners or Park Nicollet for further care and treatment

**TABLE 3:
2019 Leading Sites of Cancer Incidence**

CANCER TYPE – MALES	HEALTHPARTNERS		PARK NICOLLET	
	MALE (n=1,100)	%	MALE (n=1,253)	%
PROSTATE GLAND (includes non-analytic)	218	20	349	28
SKIN (includes non-analytic)	154	14	242	19
BRONCHUS & LUNG	121	11	91	7
BLOOD & BONE MARROW	77	7	82	7
URINARY BLADDER	63	6	72	6
COLON & RECTUM	81	7	70	6
KIDNEY	50	5	63	5
LYMPH NODES	60	5	60	5
PANCREAS	29	3	31	2
ESOPHAGUS	22	2	26	2

CANCER TYPE – FEMALES	HEALTHPARTNERS		PARK NICOLLET	
	FEMALE (n=1,363)	%	FEMALE (n=1,529)	%
BREAST	519	38	624	41
SKIN (includes non-analytic)	113	8	202	13
BRONCHUS & LUNG	132	10	155	10
CORPUS UTERI	66	5	89	6
COLON & RECTUM	80	6	85	6
BLOOD & BONE MARROW	61	4	58	4
LYMPH NODES	41	3	51	3
THYROID GLAND	40	3	37	2
PANCREAS	34	2	36	2
OVARY	32	2	26	2
KIDNEY	27	2	24	2
URINARY BLADDER	24	2	22	1



Quality performance

Regions Hospital Cancer Care Center

Improving infusion scheduling

A quality improvement project was initiated that focused on infusion scheduling. The issue was the cancer center's increase in patients requiring infusions, resulting in patient volumes that were difficult to sustain. When the project started, there were overbookings as well as gaps in scheduling that resulted in staff working late. The scope of the work included infusion chair and clinic appointment scheduling. The goals were to decrease the patient wait times by 30% while increasing nurse or staff satisfaction by 25% (from a baseline of 55-65%). The project was implemented in April using iQueue Lean Taas scheduling software. We expect further positive results in 2021.

Monitoring COVID-19 cases

Due to the impact of COVID-19, the oncology program actively monitors all patients and staff who have received virus testing and their results. Randy Hurley, MD, has taken the lead on this project that includes an EPIC report that tracks the number of COVID tests performed on our patients, the number of positive tests and clinical outcomes. It also includes a summary of the new COVID policies and procedures that have been implemented. In May, there were 580 test performed compared to 1,213 in July. The number of positive tests has varied over the weeks but those numbers also reflect an overall increase in testing more patients. Care protocols were adjusted as needed based on the number of cases.

Park Nicollet Frauenshuh Cancer Center

New protocol for neutropenic fevers

A project was initiated to evaluate our patients receiving treatment who develop neutropenic fever with a goal of reducing the need for inpatient care. For the outpatient setting, a neutropenic fever evaluation plan was created and is now available in the cancer center. For our patients in the hospital, new protocols for neutropenic fever have been developed and are being utilized by our medical oncologists as well as hospital staff who provide care 24 hours a day.



Give hope. Give possibility.

In 2019, through Regions Hospital Foundation and Park Nicollet Foundation, nearly 980 donors gave more than \$1,600,000 to support meaningful care for those affected by cancer at Regions Hospital Cancer Care Center and Park Nicollet Frauenshuh Cancer Center.

Your generous gifts support:

- Basic needs assistance
- Care navigation assistance
- Classes and support groups
- Clinical cancer research
- Integrative therapies including music and massage therapy
- Non-moving patient care model
- Survivorship programming



Be a part of our mission in action
Donate at parknicollet.com/give or contact us at foundation@parknicollet.com.



Make a difference today
Donate at regionshospital.com/donate or contact us at rhf@healthpartners.com.



"I'm not just a survivor, I'm a thriver, and it's all thanks to the compassionate care and emotional support I received from the staff and volunteers. I would recommend Frauenshuh Cancer Center to anyone."

Mary Hurlbert, patient and donor



"Dr. Jahagirdar has phenomenal expertise; a wonderful, caring heart; and a tremendous commitment to his patients and their families. He makes you feel like you are the only person in the world when you are in his care."

Tom Kingston, board member and donor, next to his brother and former patient, John



Cancer committee members 2020

Our cancer committees meet quarterly to review all aspects of our program. This includes information related to cancer conferences, community outreach, research and quality improvement, as well as all the teams involved in cancer care.

HealthPartners

Kathryn Baxstrom, MD
Medical Oncology

Sue Braaten, RHIT, CTR
Oncology Registry

E. J. Buckley, MD
Breast Surgeon

Linda Christinsen-Rengel, NP
Breast Health Center

Christine Colbach, MD
Pathology

Kevin Collis, RN, OCN
Nurse Navigator

Kim Duffy, RD
Food and Nutritional Services

Holly Guida, RN-BSN, MBA
Oncology Program Manager

Danielle Hermes
Quality Performance Improvement

Laura Holasek
Director, Oncology

Randy Hurley, MD
Medical Oncology

Carol Jirik, RN, BA
Nurse Manager, Cancer Center

Cindy Johnston, MS, LGC
Genetic Counselor

Michele Lacy, RN, BSN, OCN
Director, Research

Pam Mason, MS
American Cancer Society

Gretchen Niemioja, MD
Rehabilitation Services

Trisha Prescott, MD
Radiology

James Risser, MD
Internal Medicine, Palliative Care

Rob Ruff
Pastoral Care

Miguel Ruiz Diaz, MD
Hospice Medical Director

James Schlaefter, MD
General Surgery, Surgical Oncology
(Cancer Liaison Fellow,
American College of Surgeons)

Denise Shannon
Lead Oncology Social Worker

Charles Shideman, MD
Radiation, Oncology

Jane Siekkinen, BS, CTR
Oncology Registry Manager

Lashonda Soma, MD
Radiology

Bonnie Sweeney, RN
Nursing

Beth Werner, RN, MHA
HealthPartners Hospice
and Palliative Care

Park Nicollet

Kathryn Baxstrom, MD
Medical Oncology

Christopher Chow, MD
Colon and Rectal Surgery

Levi Downs, MD
Gynecology Oncology

Justin Eklund, MS, CCRP
Clinical Research

Kelly Furda, MD
Radiologist, Jane Brattan Breast Center

Nancy Gelle, BSN, RN
Palliative Care,
Home Care, Hospice

Howard Haines, MD
Emergency Medicine

Michael Haley, MD
Radiation Oncology

Kristin Hanrahan
Quality Improvement

Megan Hanson, MS, CGC
Genetics

Keith Heaton, MD
General Surgery, Surgical Oncology
(Cancer Liaison Fellow,
American College of Surgeons)

Joanna Hill, MBA, CCRP
Research Manager

Laura Holasek
Director, Oncology

Anne Hopkins, RN, OCN
Oncology Program Manager

Michele Lacy, RN, BSN, OCN
Director, Research

Pamela Mason, MS
American Cancer Society

Matt McCoy, MD
Pathology

Vicki Norton, BSN, OCN, RN
Nursing

Carol Ann Petersen, LICSW, MAHS
Patient Support and Education

Jocelyn Rieder, MD
Urology

Emily Schoh, RN
Nursing

Bryan Schuler, PharmD, BCOP
Pharmacy

Jane Siekkinen, BS, CTR
Oncology Registry Manager

Paul Spilde, PT
Rehabilitation Services

Janet Stark, BCC
Chaplain

Eric Weinberg, MD
Diagnostic Radiology

Mark Wilkowske, MD
Medical Oncology



Oncology clinician team

Lindsay Albert, NP-AGPC	Michael Haley, DO	Kathryn Moore, MD
Daniel Anderson, MD, MPH	Robert Haselow, MD	Sally Mullany, MD
Annie Barlow, MPAS, PA-C	Keith Heaton, MD	Gretchen Niemioja, MD
Kathryn Baxstrom, MD	Jason Hoiness, PharmD	Richard Peterson, MD
Turang Behbahani, MD	Peter Hurley, MD	Karen Rabenau, MD
Kacy Berquist, MSN, APRN, NP-C	Randy Hurley, MD	Brian Rank, MD
Michael Blazer, MD	Lisa Huset, PA-C	Anne Reiber, ANP, GNP
Joel Carter, MD	Lisa Illig, MD	Jim Risser, MD
Cathleen Chen, MD	Sarah Jax, NP-AGPC	James Schlaefel, MD
Candy Corey, MD	Jeffrey Jaffe, MD	Daniel Schneider, MD
Janel Cox, MD	Balkrishna Jahagirdar, MBBS	Melissa Sherman, MD
Kurt Demel, MD	Kathryn Jelle, PA-C	Charles Shideman, MD
Christine Ding, MD	Yan Ji, MD	Amy Spomer, MD
Levi Downs, MD	Khalid Ali Kambal, MB BCh	Cierra Sroda, PA-C
Dave Drone, PharmD	Kendra Kubiak, MD	Somu Suppiah, MD
Arkadiusz Dudek, MD, PhD	Priya Kumar, MD	Deanna Teoh, MD
Mary Ehresman, FNP, ADCN	Brenda Larson, MD	Kandice Tolic, NP-WH
Kristen Engstrom, NP-AGPC	Rachel Lerner, MD	Bryan Trottier, MD
Kelsa Evans, PA-C	Adrienne Mallen, MD	Jayanthi Vijayakumar, MBBS, MS
Brad Farrell, PharmD	Sarah Manuels, MPAS, PA-C, MPH	Punit Wadhwa, MBBS
Lori Fewer, CFNP	Steven McCormack, MD	Mark Wilkowske, MD
Chitra Ganesan, MBBS	Mark Menge, MD	Kelly Young, DNP-F
Warren Goodman, MD	Craig Mescher, MD	Dylan Zylla, MD, MS

HealthPartners Institute

Advancing health and well-being through research and education

We are research and education together at HealthPartners. We conduct hundreds of research studies each year to improve lives. We also support clinical learning at HealthPartners through the training of many health professionals. We are a member of the national Cancer Research Network and offer unique and novel therapies through an Early Phase Therapeutics Program using the newest investigational drugs available for research. Through clinical trials, we support patients with cancer in our community and contribute to life-changing science around the globe.

For more information, visit healthpartners.com/institute.



PARK NICOLLET FRAUENSHUH CANCER CENTER
REGIONS HOSPITAL CANCER CARE CENTER
PARK NICOLLET CLINIC & SPECIALTY CENTER – BURNSVILLE
PARK NICOLLET CLINIC & SPECIALTY CENTER – MAPLE GROVE
HUTCHINSON HEALTH CANCER CENTER
LAKEVIEW HOSPITAL CANCER CARE – STILLWATER

To make an appointment, call:

Park Nicollet Frauenshuh Cancer Center
952-993-3248

Regions Hospital Cancer Care Center
651-254-3572

Park Nicollet Clinic & Specialty Center – Burnsville
952-993-3248

Park Nicollet Clinic & Specialty Center – Maple Grove
952-993-3248

Hutchinson Health Cancer Center
320-484-4695

Lakeview Hospital Cancer Care – Stillwater
651-430-4790

For more information or to make
a referral, contact Laura Holasek at
laura.holasek@parknicollet.com or
651-254-4656.

healthpartners.com/cancer